Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering

Executive Summary

• Innocan Pharma Corp. announced it expects to list its common shares on NYSE American around January 30, 2026, pending approval.
• The company will conduct a concurrent offering of its securities; details will be disclosed in forthcoming SEC and SEDAR filings.
• Upon the NYSE listing, trading on the OTCQB market will cease, while CSE trading under “INNO” will continue.

Key Details

• Anticipated NYSE American listing date: on or about January 30, 2026 (subject to exchange approval and compliance).
• Current OTCQB trading expected to end on or about January 29, 2026; shares will then trade exclusively on the Canadian Securities Exchange (CSE) under “INNO”.
• A concurrent securities offering is planned in connection with the listing; specifics (price, size, structure, use of proceeds) will be provided via SEC and SEDAR filings.
• No action required from existing shareholders prior to the NYSE listing.
• The release includes standard forward‑looking statements and risk disclosures but does not contain any offer or solicitation in jurisdictions where such would be unlawful.

Notable Quotes

• Iris Bincovich, CEO: “We are excited to advance our capital market presence by moving to NYSE American, which we believe will enhance visibility for our innovative drug‑delivery platforms and support future growth initiatives.” (quote paraphrased from the release)